Fig. 1From: Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based studyPatient-reported average number of good days/month before and after starting eptinezumabPatients were asked, “On average, how many good days per month did you experience before/after starting eptinezumab? Please indicate the number of days from 1‒31.”Back to article page